Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

Cell

Volumn 138, Issue 2, 2009, Pages 245-256

  Wang, Qianben ^a,b   Li, Wei ^c   Zhang, Yong ^d   Yuan, Xin ^e   Xu, Kexin ^a   Yu, Jindan ^f   Chen, Zhong ^b   Beroukhim, Rameen ^a,g   Wang, Hongyun ^e   Lupien, Mathieu ^a   Wu, Tao ^a   Regan, Meredith M ^d   Meyer, Clifford A ^d   Carroll, Jason S ^h   Manrai, Arjun Kumar ^d   Jänne, Olli A ⁱ   Balk, Steven P ^e   Mehra, Rohit ^f   Han, Bo ^f   Chinnaiyan, Arul M ^f   Rubin, Mark A ^j   True, Lawrence ^k   Fiorentino, Michelangelo ^a   Fiore, Christopher ^a   Loda, Massimo ^a   Kantoff, Philip W ^a   Liu, X Shirley ^d   Brown, Myles ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Dan L Duncan Cancer Center   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Division of Hematology and Oncology   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

more..

Author keywords

HUMDISEASE

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CELL PROTEIN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HISTONE; PROTEIN UBE2C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; EPIGENETICS; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; RNA INTERFERENCE; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING;

EID: 67650758019     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2009.04.056     Document Type: Article

References (48)

1. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., Wei G., Chepelev I., and Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 129 (2007) 823-837
2. Bernstein B.E., Kamal M., Lindblad-Toh K., Bekiranov S., Bailey D.K., Huebert D.J., McMahon S., Karlsson E.K., Kulbokas III E.J., Gingeras T.R., et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120 (2005) 169-181
3. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 (2005) 33-43
4. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., and Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10 (2004) 33-39
5. Comstock C.E., and Knudsen K.E. The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. Cell Cycle 6 (2007) 1307-1313
6. Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch A., Hittmair A., Bartsch G., Utermann G., Schneider M.R., Parczyk K., et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 81 (1999) 242-251
7. Dai M., Wang P., Boyd A.D., Kostov G., Athey B., Jones E.G., Bunney W.E., Myers R.M., Speed T.P., Akil H., et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33 (2005) e175
8. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351 (2004) 1488-1490
9. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 (2001) 34-45
10. Girard F., Strausfeld U., Fernandez A., and Lamb N.J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67 (1991) 1169-1179
11. Group P.C.T.C. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
12. Haag P., Bektic J., Bartsch G., Klocker H., and Eder I.E. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J. Steroid Biochem. Mol. Biol. 96 (2005) 251-258
13. Hagege H., Klous P., Braem C., Splinter E., Dekker J., Cathala G., de Laat W., and Forne T. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat. Protocols 2 (2007) 1722-1733
14. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 25 (2004) 276-308
15. Heintzman N.D., Stuart R.K., Hon G., Fu Y., Ching C.W., Hawkins R.D., Barrera L.O., Van Calcar S., Qu C., Ching K.A., et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39 (2007) 311-318
16. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., and Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003) 249-264
17. Johnson D.S., Li W., Gordon D.B., Bhattacharjee A., Curry B., Ghosh J., Brizuela L., Carroll J.S., Brown M., Flicek P., et al. Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res. 18 (2008) 393-403
18. Johnson W.E., Li W., Meyer C.A., Gottardo R., Carroll J.S., Brown M., and Liu X.S. Model-based analysis of tiling-arrays for ChIP-chip. Proc. Natl. Acad. Sci. USA 103 (2006) 12457-12462
19. Kouzarides T. Chromatin modifications and their function. Cell 128 (2007) 693-705
20. Lin J., Raoof D.A., Wang Z., Lin M.Y., Thomas D.G., Greenson J.K., Giordano T.J., Orringer M.B., Chang A.C., Beer D.G., et al. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia 8 (2006) 1062-1071
21. Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., Carroll J.S., Liu X.S., and Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132 (2008) 958-970
22. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
23. Pallante P., Berlingieri M.T., Troncone G., Kruhoffer M., Orntoft T.F., Viglietto G., Caleo A., Migliaccio I., Decaussin-Petrucci M., Santoro M., et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br. J. Cancer 93 (2005) 464-471
24. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351 (2004) 1513-1520
25. Prigent C., and Dimitrov S. Phosphorylation of serine 10 in histone H3, what for?. J. Cell Sci. 116 (2003) 3677-3685
26. Reddy S.K., Rape M., Margansky W.A., and Kirschner M.W. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature 446 (2007) 921-925
27. Resnitzky D., Hengst L., and Reed S.I. Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol. Cell. Biol. 15 (1995) 4347-4352
28. Rubin M.A., Zhou M., Dhanasekaran S.M., Varambally S., Barrette T.R., Sanda M.G., Pienta K.J., Ghosh D., and Chinnaiyan A.M. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287 (2002) 1662-1670
29. Ruthenburg A.J., Allis C.D., and Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol. Cell 25 (2007) 15-30
30. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23 (2005) 8253-8261
31. Schuur E.R., Henderson G.A., Kmetec L.A., Miller J.D., Lamparski H.G., and Henderson D.R. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 271 (1996) 7043-7051
32. Shang Y., Myers M., and Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 9 (2002) 601-610
33. Shao W., Keeton E.K., McDonnell D.P., and Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc. Natl. Acad. Sci. USA 101 (2004) 11599-11604
34. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., and Casero R.A. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119 (2004) 941-953
35. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., and Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66 (2006) 2815-2825
36. Sun Z., Pan J., and Balk S.P. Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res. 25 (1997) 3318-3325
37. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351 (2004) 1502-1512
38. Thalmann G.N., Sikes R.A., Wu T.T., Degeorges A., Chang S.M., Ozen M., Pathak S., Chung L.W., et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44 (2000) 91-103
39. Tomlins S.A., Mehra R., Rhodes D.R., Cao X., Wang L., Dhanasekaran S.M., Kalyana-Sundaram S., Wei J.T., Rubin M.A., Pienta K.J., et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39 (2007) 41-51
40. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98 (2001) 5116-5121
41. Varambally S., Yu J., Laxman B., Rhodes D.R., Mehra R., Tomlins S.A., Shah R.B., Chandran U., Monzon F.A., Becich M.J., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8 (2005) 393-406
42. Wagner K.W., Sapinoso L.M., El-Rifai W., Frierson H.F., Butz N., Mestan J., Hofmann F., Deveraux Q.L., and Hampton G.M. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23 (2004) 6621-6629
43. Wang H., Leav I., Ibaragi S., Wegner M., Hu G.F., Lu M.L., Balk S.P., and Yuan X. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 68 (2008) 1625-1630
44. Wang Q., Carroll J.S., and Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol. Cell 19 (2005) 631-642
45. Wang Q., Li W., Liu X.S., Carroll J.S., Janne O.A., Keeton E.K., Chinnaiyan A.M., Pienta K.J., and Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27 (2007) 380-392
46. Wang Q., Sharma D., Ren Y., and Fondell J.D. A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J. Biol. Chem. 277 (2002) 42852-42858
47. Xu Y., Chen S.Y., Ross K.N., and Balk S.P. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 66 (2006) 7783-7792
48. Yu D.C., Sakamoto G.T., and Henderson D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59 (1999) 1498-1504